It's an investigational drug currently in Phase 3 clinical trials Eli Lilly's TRIUMPH Phase 3 program includes multiple trials for obesity, type 2 diabetes, NASH, and cardiovascular outcomes Expected timeline: FDA submission in 2026, potential approval in 20272028 Phase 2 results showed 24.2% weight loss at 48 weeks, the highest ever recorded for a GLP-1 class medication How to access now: Clinical trial enrollment (free), compounding pharmacies (with important legal caveats), or research peptides (grey market) When approved, retatrutide will be the first triple-agonist obesity medication (GLP-1 + GIP + glucagon) Is Retatrutide FDA Approved
February 2024 outfit looks better Selena Gomez has always embraced herself confidently, showing pride in her appearance no matter the changes
Soy, Soy Isoflavones, and Protein Intake in Relation to Mortality from All Causes, Cancers, and Cardiovascular Diseases: A Systematic Review and DoseResponse Meta-Analysis of Prospective Cohort Studies
Red blood cells in biology and translational medicine: natural vehicle inspires new biomedical applications
Most patients find it easier than expected
